Flumequine (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Flumequine" in English language version.

refsWebsite
Global rank English rank
4th place
4th place
2nd place
2nd place
447th place
338th place
1st place
1st place
11th place
8th place
low place
low place
68th place
117th place
5th place
5th place
5,449th place
3,875th place
8,548th place
low place
26th place
20th place
low place
low place
low place
low place
low place
low place
318th place
411th place

88chem.com

academy.org.uk

doi.org

europa.eu

ema.europa.eu

fao.org

  • Francis PG, Wells RJ. "Flumequine". Pymble, Australia: Australian Government Analytical Laboratories.

fda.gov

fda.gov

accessdata.fda.gov

freepatentsonline.com

jstor.org

  • Hosomi J, Maeda A, Oomori Y, Irikura T, Yokota T (1988). "Mutagenicity of Norfloxacin and AM-833 in Bacteria and Mammalian Cells". Reviews of Infectious Diseases. 10 (Supplement 1): S148–9. JSTOR 4454399.

medindia.net

nih.gov

pubmed.ncbi.nlm.nih.gov

  • Nelson JM, Chiller TM, Powers JH, Angulo FJ (April 2007). "Fluoroquinolone-resistant Campylobacter species and the withdrawal of fluoroquinolones from use in poultry: a public health success story". Clinical Infectious Diseases. 44 (7): 977–980. doi:10.1086/512369. PMID 17342653.
  • Kawahara S (December 1998). "[Chemotherapeutic agents under study]". Nihon Rinsho. Japanese Journal of Clinical Medicine (in Japanese). 56 (12): 3096–3099. PMID 9883617.
  • Schena FP, Gesualdo L, Caracciolo G (January 1988). "A multicentre study of flumequine in the treatment of urinary tract infections". The Journal of Antimicrobial Chemotherapy. 21 (1): 101–106. doi:10.1093/jac/21.1.101. PMID 3356617.
  • King DE, Malone R, Lilley SH (May 2000). "New classification and update on the quinolone antibiotics". American Family Physician. 61 (9): 2741–2748. PMID 10821154.
  • Takahashi H, Hayakawa I, Akimoto T (2003). "[The history of the development and changes of quinolone antibacterial agents]". Yakushigaku Zasshi (in Japanese). 38 (2): 161–179. PMID 15143768.
  • Sirbat D, Saudax E, Hurault de Ligny B, Hachet E, Abellan P, George JL (1983). "[Serous macular detachment and treatment with flumequine (Apurone = urinary antibacterial). Apropos of 2 cases]". Bulletin des Sociétés d'Ophtalmologie de France (in French). 83 (8–9): 1019–1021. PMID 6378414.
  • Hurault de Ligny B, Sirbat D, Kessler M, Trechot P, Chanliau J (1984). "[Ocular side effects of flumequine. 3 cases of macular involvement]". Therapie (in French). 39 (5): 595–600. PMID 6506018.
  • Ball P (July 2000). "Quinolone generations: natural history or natural selection?". The Journal of Antimicrobial Chemotherapy. 46 (Suppl T1): 17–24. doi:10.1093/oxfordjournals.jac.a020889. PMID 10997595.
  • Dubois A, Janbon C, Pignodel C, Marty-Double C (February 1983). "[Immunoallergic hepatitis induced by flumequine]". Gastroenterologie Clinique et Biologique (in French). 7 (2): 217–218. PMID 6840466.
  • Pinzani V, Gennaro G, Petit P, Blayac JP (1992). "[Anaphylactic shock induced by flumequine]". Therapie (in French). 47 (5): 440. PMID 1299991.
  • Marsepoil T, Blin F, Lo JM, Horel D'Ancona F, Sebbah JL (September 1985). "[A case of anaphylactic shock induced by flumequine]". Presse Médicale (in French). 14 (32): 1712. PMID 2932732.
  • Drlica K, Zhao X (September 1997). "DNA gyrase, topoisomerase IV, and the 4-quinolones". Microbiology and Molecular Biology Reviews. 61 (3): 377–392. doi:10.1128/mmbr.61.3.377-392.1997. PMC 232616. PMID 9293187.
  • Robinson MJ, Martin BA, Gootz TD, McGuirk PR, Osheroff N (April 1992). "Effects of novel fluoroquinolones on the catalytic activities of eukaryotic topoisomerase II: Influence of the C-8 fluorine group". Antimicrobial Agents and Chemotherapy. 36 (4): 751–756. doi:10.1128/aac.36.4.751. PMC 189387. PMID 1323952.
  • Sissi C, Palumbo M (November 2003). "The quinolone family: from antibacterial to anticancer agents". Current Medicinal Chemistry. Anti-Cancer Agents. 3 (6): 439–450. doi:10.2174/1568011033482279. PMID 14529452. The present review focuses on the structural modifications responsible for the transformation of an antibacterial into an anticancer agent. Indeed, a distinctive feature of drugs based on the quinolone structure is their remarkable ability to target different type II topoisomerase enzymes. In particular, some congeners of this drug family display high activity not only against bacterial topoisomerases but also against eukaryotic topoisomerases and are toxic to cultured mammalian cells and in vivo tumor models
  • Hussy P, Maass G, Tümmler B, Grosse F, Schomburg U (June 1986). "Effect of 4-quinolones and novobiocin on calf thymus DNA polymerase alpha primase complex, topoisomerases I and II, and growth of mammalian lymphoblasts". Antimicrobial Agents and Chemotherapy. 29 (6): 1073–1078. doi:10.1128/AAC.29.6.1073. PMC 180502. PMID 3015015.
  • Forsgren A, Bredberg A, Pardee AB, Schlossman SF, Tedder TF (May 1987). "Effects of ciprofloxacin on eucaryotic pyrimidine nucleotide biosynthesis and cell growth". Antimicrobial Agents and Chemotherapy. 31 (5): 774–779. doi:10.1128/AAC.31.5.774. PMC 174831. PMID 3606077.
  • Gootz TD, Barrett JF, Sutcliffe JA (January 1990). "Inhibitory effects of quinolone antibacterial agents on eucaryotic topoisomerases and related test systems". Antimicrobial Agents and Chemotherapy. 34 (1): 8–12. doi:10.1128/AAC.34.1.8. PMC 171510. PMID 2158274.
  • Lawrence JW, Darkin-Rattray S, Xie F, Neims AH, Rowe TC (February 1993). "4-Quinolones cause a selective loss of mitochondrial DNA from mouse L1210 leukemia cells". Journal of Cellular Biochemistry. 51 (2): 165–174. doi:10.1002/jcb.240510208. PMID 8440750. S2CID 41291987.
  • Elsea SH, Osheroff N, Nitiss JL (July 1992). "Cytotoxicity of quinolones toward eukaryotic cells. Identification of topoisomerase II as the primary cellular target for the quinolone CP-115,953 in yeast". The Journal of Biological Chemistry. 267 (19): 13150–13153. doi:10.1016/S0021-9258(18)42185-0. PMID 1320012.
  • Suto MJ, Domagala JM, Roland GE, Mailloux GB, Cohen MA (December 1992). "Fluoroquinolones: relationships between structural variations, mammalian cell cytotoxicity, and antimicrobial activity". Journal of Medicinal Chemistry. 35 (25): 4745–4750. doi:10.1021/jm00103a013. PMID 1469702.
  • Enzmann H, Wiemann C, Ahr HJ, Schlüter G (April 1999). "Damage to mitochondrial DNA induced by the quinolone Bay y 3118 in embryonic turkey liver". Mutation Research. 425 (2): 213–224. doi:10.1016/S0027-5107(99)00044-5. PMID 10216214.
  • Kashida Y, Sasaki YF, Ohsawa K, Yokohama N, Takahashi A, Watanabe T, Mitsumori K (October 2002). "Mechanistic study on flumequine hepatocarcinogenicity focusing on DNA damage in mice". Toxicological Sciences. 69 (2): 317–321. doi:10.1093/toxsci/69.2.317. PMID 12377980.
  • Thomas A, Tocher J, Edwards DI (May 1990). "Electrochemical characteristics of five quinolone drugs and their effect on DNA damage and repair in Escherichia coli". The Journal of Antimicrobial Chemotherapy. 25 (5): 733–744. doi:10.1093/jac/25.5.733. PMID 2165050.
  • Daudon M, Protat MF, Réveillaud RJ (1983). "[Detection and diagnosis of drug induced lithiasis]". Annales de Biologie Clinique (in French). 41 (4): 239–249. PMID 6139048.
  • Rincé C, Daudon M, Moesch C, Rincé M, Leroux-Robert C (May 1987). "Identification of flumequine in a urinary calculus". Journal of Clinical Chemistry and Clinical Biochemistry. 25 (5): 313–314. PMID 3612030.
  • Reveillaud RJ, Daudon M (October 1983). "[Drug-induced urinary lithiasis]". Presse Médicale (in French). 12 (38): 2389–2392. PMID 6138768.
  • Christ W (October 1990). "Central nervous system toxicity of quinolones: human and animal findings". The Journal of Antimicrobial Chemotherapy. 26 (Suppl B): 219–225. doi:10.1093/jac/26.suppl_b.219. PMID 2124211.
  • Defoin JF, Debonne T, Rambourg MO, Seraphin J, Buffet M, Jaussaud M, et al. (1990). "[Acute psychiatric syndrome and quinolones]". Journal de Toxicologie Clinique et Expérimentale (in French). 10 (7–8): 469–472. PMID 2135062.
  • Rampa S, Caroli F (1991). "[Neuropsychiatric manifestations and quinolones. Apropos of a case]". L'Encephale (in French). 17 (6): 511–514. PMID 1666873.
  • Vermeersch G, Filali A, Marko J, Catteau JP, Couture A (1990). "[Photophysical evaluation of photosensitization by various quinolones]". Journal de Pharmacie de Belgique (in French). 45 (5): 299–305. PMID 1964964.
  • Revuz J, Pouget F (1983). "[Photo-onycholysis caused by Apurone]". Annales de Dermatologie et de Venereologie (in French). 110 (9): 765. PMID 6660786.
  • Lacarelle B, Blin O, Audebert C, Auquier P, Karsenty H, Horriere F, Durand A (1994). "The quinolone, flumequine, has no effect on theophylline pharmacokinetics". European Journal of Clinical Pharmacology. 46 (5): 477–478. doi:10.1007/bf00191915. PMID 7957547. S2CID 97621.

ncbi.nlm.nih.gov

pharmacorama.com

semanticscholar.org

api.semanticscholar.org

  • Lawrence JW, Darkin-Rattray S, Xie F, Neims AH, Rowe TC (February 1993). "4-Quinolones cause a selective loss of mitochondrial DNA from mouse L1210 leukemia cells". Journal of Cellular Biochemistry. 51 (2): 165–174. doi:10.1002/jcb.240510208. PMID 8440750. S2CID 41291987.
  • Lacarelle B, Blin O, Audebert C, Auquier P, Karsenty H, Horriere F, Durand A (1994). "The quinolone, flumequine, has no effect on theophylline pharmacokinetics". European Journal of Clinical Pharmacology. 46 (5): 477–478. doi:10.1007/bf00191915. PMID 7957547. S2CID 97621.

web.archive.org

who-umc.org

worldcat.org

  • Francis PG, Wells RJ (1998). "Flumequine". Joint FAO/WHO Expert Committee on Food Additives. Residues of some veterinary drugs in animals and foods. Rome: Food and Agriculture Organization. ISBN 92-5-104128-8. OCLC 39798999.